Cemiplimab for advanced lung cancer with high PD-L1
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV or stage IIIB/C non-small cell lung cancer that cannot be treated with surgery or standard chemo-radiation.
- Your tumor has a high level of PD-L1 (at least 50%).
- You have not had any prior chemotherapy or radiation for advanced lung cancer.
- You are in good physical condition (able to care for yourself and be up and about more than half of waking hours).
- You do not have certain gene changes (EGFR, ALK, ROS1) that can be treated with targeted pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the immunotherapy drug cemiplimab, given before and after surgery, can help treat early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. If you have stage II or IIIA lung cancer that can be surgically removed and your tumor has PD-L1 expression of 50% or more, you may be eligible.
This trial tests a combination of immunotherapy (cemiplimab) and chemotherapy for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. It looks at whether this treatment works better when certain immune cells in the blood are high.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This study tests a combination of an immunotherapy drug (cemiplimab) plus chemotherapy for advanced squamous non-small cell lung cancer. Researchers want to see if this treatment works better in people whose tumors have a certain enzyme level.
This trial tests a personalized chemotherapy approach for people with early-stage (stage II–IIIB) non-small cell lung cancer that can be removed with surgery. It uses the tumor's PD-L1 level (a marker that helps the immune system attack cancer) to guide treatment before surgery, aiming to improve outcomes.
This trial tests giving Cemiplimab, an immunotherapy drug that helps your immune system fight cancer, before surgery to remove early stage non-small cell lung cancer. It aims to see if this approach can improve outcomes for people with small tumors that are more aggressive based on PET scan activity or cell appearance.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.